Peptide Stocks in Focus After HHS Policy Shift as Peptide…
By PressRelease
AI summary of the source article
The US Department of Health and Human Services proposed an interim policy allowing pharmacies to compound certain peptides. Alongside stock movements, crypto project Peptide Swap launched an alpha marketplace utilizing blockchain escrow and reviews for peptide transactions.
Why it matters
The compounding policy matters most for consumer-facing platforms like Hims, which sell directly to patients.
Key facts
- HHS submitted an interim access policy to the White House allowing compounding pharmacies to produce peptides such as BPC-157.
- Hims & Hers Health shares rose approximately 6% following the policy news, with the potential market estimated between $2 billion and $3 billion.
- Peptide Swap launched an alpha decentralized marketplace featuring escrow orders and public reviews to verify sellers and transactions.
Source excerpt · FinanceFeeds
Peptides have become a market story. Last week the US Department of Health and Human Services (HHS) sent the White House a plan titled "Interim Access Policy for Compounding Using Certain Peptides", which would open a path for pharmacies to make popular peptides such as BPC-157. Searches for "peptide" spiked on Google the same week, and Hims & Hers Health (HIMS) closed up about 6% on Thursday, 15…